On May 4, 2022, BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF Derived Small Extracellular Vesicles Display Superior Macrophage Immunomodulation Compared with Vesicles Derived from Naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, California. The poster will be presented by Kim Thacker, MD, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
Login Or Register To Read Full Story